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Abstract 
Background: Dulaglutide, a synthetic once-weekly, injectable human glucagon-like peptide 1 
(GLP1) analogue lowers blood glucose, body weight, appetite, and blood pressure. Its effect on 
cardiovascular outcomes is unknown.  
Methods: People with type 2 diabetes, aged 50 or older, a HbA1c ≤9.5%, and either a previous 
cardiovascular (CV) event, evidence of CV disease or > 2 CV risk factors were randomly 
allocated to a weekly subcutaneous injection of either dulaglutide (1.5 mg) or placebo and 
followed within the Researching cardiovascular Events with a Weekly INcretin in Diabetes 
(REWIND) trial every 3 to 6 months. The primary cardiovascular outcome is the first occurrence 
of the composite of cardiovascular death or non-fatal MI or nonfatal stroke. Secondary outcomes 
include each component of the primary composite cardiovascular outcome, a composite clinical 
microvascular outcome comprising retinal or renal disease, hospitalization for unstable angina, 
heart failure requiring hospitalization or an urgent heart failure visit, and all-cause mortality. 
Follow-up will continue until the accrual of 1200 confirmed primary outcomes. 
Results: Recruitment of 9901 participants (mean age 66, 46% women) occurred in 370 sites 
located in 24 countries over a period of 2 years. The mean duration of diabetes was 10 years, 
mean baseline HbA1c was 7.3 %, and 31% had prior cardiovascular disease. 
Conclusion: The REWIND trial’s international scope, high proportion of women, high 
proportion of people without prior cardiovascular disease, and inclusion of participants whose 
mean baseline HbA1c was 7.3% suggests that its cardiovascular and safety findings will be 
directly relevant to the typical middle-aged patient seen in general practice throughout the world.  
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Introduction 
 
The incidence of cardiovascular events in people with type 2 diabetes is about twice as high as it 
is in similar individuals without type 2 diabetes1. This higher incidence is caused by a number of 
risk factors related to the causes and consequences of dysglycemia2, obesity, dyslipidemia, 
hypertension, and endothelial damage or dysfunction3,4. Such abnormalities have provided the 
basis for an array of randomized, controlled trials of the effect of both glucometabolic and non-
glucometabolic interventions on cardiovascular events in people with diabetes. To date trials 
with non-glucometabolic therapies have shown that statins5, renin angiotensin system 
modulators6,7, other blood pressure lowering agents8,9, and the Mediterranean diet10 can reduce 
cardiovascular events, whereas lifestyle interventions focused on weight reduction have, to date, 
had a neutral effect11. Trials of glucometabolic therapies in people with diabetes have shown that 
intensive glucose lowering modestly reduces cardiovascular outcomes mainly due to an effect on 
ischemic heart disease12-15 and has an uncertain effect on mortality16. Other studies that focused 
on drug effects rather than glucose lowering effects have shown that insulin sensitizing 
approaches have the same effect on cardiovascular outcomes as insulin providing approaches17; 
pioglitazone has a mixed effect on cardiovascular outcomes18, basal insulin19 and DPP4 
inhibitors20-22 have a neutral effect on cardiovascular outcomes; and one SGLT2 inhibitor, 
empagliflozin, reduces cardiovascular and total mortality as well as heart failure 
hospitalization23.  
 
Glucagon-like Peptide 1 (GLP1) receptor agonists are analogues of natural GLP1, a 
gastrointestinal hormone which is secreted in response to food intake and increases insulin 
secretion in response to glucose, reduces glucagon secretion, reduces appetite, and slows gastric 
emptying24. Biologic effects of this hormone on the circulatory system suggest that it may also 
have salutary cardiovascular effects. Because natural GLP1 has a very short half-life, analogues 
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that resist degradation and that are given once (liraglutide, lixisenatide) or twice (exenatide) 
daily, weekly (long-acting exenatide, dulaglutide, semaglutide, albiglutide) or less frequently 
(implanted subcutaneous exenatide pump) have been developed25. Clinical trials of these 
analogues have shown that these drugs lower glucose levels without promoting hypoglycemia, 
modestly lower blood pressure, increase heart rate by 2-4 beats per minute, and promote modest 
weight loss24.  
 
The effects of some of these agents on cardiovascular outcomes have also been reported. Thus, 
once daily lixisenatide had a neutral effect on cardiovascular outcomes following a diagnosis of 
acute coronary syndrome in 6068 people of mean age 60 years whose mean baseline HbA1c was 
7.7% and who were treated for a median of 2.1 years26; once daily liraglutide reduced 
cardiovascular events as well as cardiovascular deaths in 9340 people of mean age 64 years 
whose mean baseline HbA1c was 8.7% and who were followed for a median of 3.8 years27; and 
once weekly semaglutide reduced cardiovascular events and stroke in 3297 people of mean age 
65 years whose mean baseline HbA1c was 8.7% and who were followed for a median of 2.1 
years28.  
 
Dulaglutide is a synthetic analogue of human GLP1 that structurally comprises 2 GLP1 receptor 
agonist molecules that are covalently linked to 1 IgG4 heavy chain by a small peptide linker. It 
has pharmacologic half-life of 5 days, which allows it to be administered as a weekly 
subcutaneous injection29. Clinical trials have shown that doses of 0.75 to 1.5 mg weekly reduce 
HbA1c as well as body weight, appetite, and blood pressure30. A meta-analysis of randomized 
controlled trials comprising 6010 individuals with diabetes followed for a median of 
approximately one year reported a neutral effect on the first occurrence of nonfatal myocardial 
infarction, nonfatal stroke, hospitalization for unstable angina, or cardiovascular death31. When 
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given alone the drug does not cause hypoglycemia. However, like other GLP1 receptor agonists, 
it can cause nausea and diarrhea in up to 10% of individuals. Dulaglutide’s effects on glucose, 
blood pressure, and weight29, together with evidence that GLP1 receptors are expressed in the 
heart and that GLP1 has anti-atherosclerotic and anti-inflammatory effects in animal studies, all 
suggest its potential for cardiovascular benefits, and support its assessment in a long-term 
cardiovascular outcomes trial.  
 
Methods 
The Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial is 
designed to determine whether the addition of a once weekly dulaglutide injection to the diabetes 
medication regimen of middle-aged and older people with type 2 diabetes safely reduces the 
incidence of cardiovascular outcomes. The selection criteria (Table 1) were designed to include 
participants who were similar to patients seen within a typical diabetes practice, who had varying 
cardiovascular risk factors, and who collectively would have an estimated cardiovascular 
outcome incidence rate of approximately 2% per year. Briefly, men and women with previous or 
newly detected diabetes whose HbA1c was ≤9.5%, and who were on 0-2 classes of oral glucose 
lowering drugs, with or without basal insulin, were recruited. People aged 50-54 years old had to 
have previous cardiovascular disease, those aged 55-59 had to have either previous 
cardiovascular disease or evidence of other vascular or renal disease, and those aged 60 and over 
were eligible if they had previous cardiovascular disease, other vascular or renal disease, or at 
least two other cardiovascular risk factors. Candidates with an estimated glomerular filtration 
rate (eGFR) <15 ml/min/1.73m2, a gastric emptying abnormality, previous pancreatitis, liver 
disease or medullary carcinoma of the thyroid gland as well as a number of other criteria were 
excluded (Table 1). 
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Ethics review boards responsible for each participating institution approved the protocol. After 
providing written, informed consent, participants were stratified by site and randomly allocated 
using blocks of 4 to either a weekly subcutaneous injection of dulaglutide (1.5 mg) or matching 
placebo and assessed every 3-6 months for the occurrence of cardiovascular and other serious 
health outcomes. At the time of run-in any participant taking a GLP1 receptor agonist or DPP4 
inhibitor had this medication stopped. HbA1c levels were measured and reported to investigators 
at least every 6 months and investigators were encouraged to manage participants’ glucose levels 
with any medication except for a GLP1 receptor agonist according to their best judgement as 
informed by local clinical practice guidelines for the management of diabetes. Investigators were 
similarly advised and periodically reminded to optimize use of cardioprotective measures 
including treatment of lipids and blood pressure, use of anti-platelet agents, and promotion of 
healthy lifestyles according to applicable guidelines4,32,33.  
 
The primary cardiovascular outcome for the REWIND trial is the first occurrence of the 
composite of either cardiovascular death or non-fatal MI or nonfatal stroke. Secondary outcomes 
include each component of the primary composite cardiovascular outcome, a composite clinical 
microvascular outcome comprising retinal or renal disease, hospitalization for unstable angina, 
heart failure requiring hospitalization or an urgent heart failure visit, and all-cause mortality. 
These and other prespecified clinical and biochemical outcomes are noted in Table 2. Safety 
outcomes include acute pancreatitis, serious and severe gastrointestinal pain, pancreatic, thyroid 
or other cancers, severe hypoglycemia, hypersensitivity reactions, and other liver, renal or 
cardiovascular events as well as drug discontinuation.  
 
All deaths and cardiovascular, pancreatic, and thyroid events (i.e. both efficacy and safety 
outcomes) are adjudicated by an external adjudication committee, which is blinded to treatment 
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allocation. Participants will continue to be followed until the trial is completed regardless of 
whether or not they have had a study outcome or whether or not they continue to take study 
medication. Unless permission is explicitly revoked, vital status at the end of the trial will be 
obtained on all randomized participants whenever possible. 
 
The REWIND trial is sponsored by Eli Lilly, site management and data collection are conducted 
by ICON Clinical Research, scientific leadership is provided by an international steering 
committee coordinated by the Population Health Research Institute in Hamilton, Canada, and 
data analysis will be conducted by the Population Health Research Institute.   
 
Sample Size 
Sample size calculations were based on a 3-year recruitment period, an anticipated primary 
outcome event rate of 2% per year in the control group, annual dropout rate of 0.15%, and a 2 
sided type 1 error of 5%. These assumptions indicated that recruitment of 9,600 patients would 
result in a total of 1,200 participants with at least 1 primary cardiovascular outcome over a 
maximum follow-up period of 8 years, and will provide 90% power to detect a hazard ratio of 
0.82 for cardiovascular events. Follow-up will end after 1,200 participants have had a primary 
cardiovascular outcome confirmed by adjudication.  
 
Statistical Analysis 
All efficacy and safety analyses will be conducted using an intention-to-treat approach that 
includes all randomized participants regardless of adherence. Baseline continuous variables will 
be summarized as either means or medians with their standard deviations or interquartile ranges, 
and categorical variables will be summarized as the number and percentage. The effect of the 
intervention on the time to the first occurrence of the primary outcome will be analyzed using 
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Cox proportional hazards models with the only independent variable being allocation to 
dulaglutide versus placebo. The proportional hazard assumption will be assessed graphically. 
Kaplan-Meier curves will also be generated along with log-rank P-values. The incidence rate per 
100 person years will be calculated for each treatment group for all key outcomes. 
 
All secondary outcomes will be analyzed in a predetermined order defined by a graphical 
approach to control the overall type I error34-36. If the null hypothesis of no effect is rejected for 
the primary outcome, the graphical testing approach allocates the alpha parsimoniously for each 
secondary outcome. A detailed description of the graphical approaches is provided in the 
Appendix.  
 
All sub-group analyses will be considered exploratory and will be conducted only for outcomes 
where the event number is at least 50. Sub-groups to be examined include gender; age below 
versus at or above the median; duration of diabetes <5 years, 5-9.9 years and 10 years or more; 
body mass index below versus at or above the median; HbA1c below versus at or above the 
median; geographical region (North America, South America and Mexico, Europe and South 
Africa, and Asia Pacific); or a prior cardiovascular event. For all sub-group analyses, an 
interaction P-value of <0.1 will be considered suggestive of an interaction. No adjustments for 
multiplicity will be performed. Other exploratory analyses will include the effect of the 
intervention on recurrent primary or secondary outcomes, other clinical outcomes, 
anthropometric and biochemical measures, cognitive function, and erectile function. 
 
An Independent Data Monitoring Committee (IDMC) meets every 6 months to review accruing 
and unblinded data within the trial and determine whether any change in the conduct of the trial 
is warranted. In addition to regular review of the findings, this committee also conducted a 
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formal interim analysis of the accruing data after approximately 61% of the primary, 
adjudication-confirmed composite endpoints have occurred. This analysis was done using an 
O’Brien-Fleming alpha spending function to control the overall 5% alpha. Nobody other than the 
members of the IDMC and its 2 unblinded statisticians have access to any accruing data 
according to allocated group. 
 
Results 
Of 12137 individuals who were screened, 9901 in 370 sites located in 24 countries were 
randomly allocated to either dulaglutide or placebo. The main reasons for not being randomized 
included not meeting eligibility criteria (68%) or a personal decision (25%). The first participant 
was randomized in August 2011 and recruitment ended one year ahead of schedule in August 
2013. As noted in Tables 3 and 4, the mean age of participants (46% women) was 66 years, the 
mean body mass index was 32 kg/m2 and 31% had a history of cardiovascular disease (defined as 
a history of myocardial infarction, ischemic stroke, revascularization, hospitalization for unstable 
angina with concordant new ischemic ECG changes, or a positive stress test with concordant 
imaging). In addition, 93% had a history of hypertension, 9% had a history of prior heart failure, 
and the mean blood pressure was 137/78 mmHg. The mean reported duration of diabetes was 10 
years, 24% were taking insulin, 81% were taking metformin, 57% were on a sulfonylurea, and 
the mean baseline HbA1c was 7.3%. An ACE inhibitor or angiotensin receptor blocker was used 
by 81%, 45% were taking a beta blocker, 66% were taking a statin at baseline, 51% were on 
acetylsalicylic acid, 8% were on other antiplatelet agents, and the mean baseline LDL cholesterol 
was 2.56 nmol/l.  
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Discussion 
REWIND is a randomized placebo-controlled trial measuring the cardiovascular effects of once 
weekly dulaglutide in patients with type 2 diabetes. This trial’s international scope, high 
proportion of women, high proportion of people without prior cardiovascular disease, and 
inclusion of participants whose mean baseline HbA1c was 7.3% means that its results will be 
directly relevant to the average middle-aged patient with diabetes seen in many programs 
throughout the world. Its focus on the “typical” middle aged patient with type 2 diabetes 
distinguishes it from the other GLP1 receptor agonist cardiovascular outcomes trials reported to 
date26-28 that are summarized in Table 5, which have focused on high-risk patients either 
following an acute coronary syndrome or with a very high prevalence of prior cardiovascular 
disease, and with higher levels of HbA1c at baseline.  
 
 
The REWIND trial is designed to determine whether people allocated to dulaglutide have a 
lower hazard of cardiovascular events than those allocated to placebo, and the planned accrual of 
1,200 first primary outcomes during a fairly long follow-up period of 7-8 years will provide high 
power to detect a clinically relevant 18% reduction. This high number of outcomes also ensures 
that there will be narrow confidence intervals around the estimated effect size.  
 
REWIND is also explicitly assessing potential side effects of dulaglutide and its effect on a large 
variety of clinically important outcomes including all-cause mortality, renal disease, 
hospitalizations for heart failure or angina, cancer (including thyroid cancer), and pancreatitis. 
Moreover, its predefined graphical testing strategy will optimize the ability to identify those 
components of the primary and secondary outcomes that are most affected by dulaglutide. These 
considerations suggest that REWIND will provide a comprehensive assessment of the clinical 
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effects of the drug and will clearly facilitate clinicians’ ability to practice evidence-based care of 
patients with type 2 diabetes who are typical of those seen on a day-to-day basis.   
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Table 1: Selection Criteria 
Key Inclusion Criteria Key Exclusion Criteria 
 Previous/new type 2 diabetes with HbA1c < 9.5% 
 Stable dose of 0, 1 or 2 oral glucose lowering drugs 
+/- basal insulin for > 3 months 
 Body mass index > 23 kg/m2 
 If age > 50, at least 1 of: prior MI; prior ischemic 
stroke; coronary revascularization > 2 years earlier; 
carotid, or peripheral revascularization > 2 months 
earlier; unstable angina hospitalization; image 
proven myocardial ischemia; or percutaneous 
coronary intervention  
 If age > 55, any of the above or at least 1 of: 
documented myocardial ischemia by stress test or 
imaging; >50% coronary, carotid, or lower extremity 
artery stenosis; ankle-brachial index <0.9; eGFR 
persistently <60 mL/minute/1.73m2; hypertension 
with LV hypertrophy; or persistent albuminuria 
 If age > 60, any of the above or at least 2 of: any 
tobacco use; use of lipid modifying therapy or a 
documented untreated LDL ≥3.4 mmol/L (130 
mg/dL) within the past 6 months; HDL-C <1.0 
mmol/L (40 mg/dL) for men and <1.3 mmol/L (50 
mg/dL) for women or triglycerides ≥2.3 mmol/L 
(200 mg/dL) within the past 6 months; use of > 1 
blood pressure drug or untreated SBP ≥140 mm Hg 
or DBP ≥95 mmHg; or waist-to-hip ratio >1.0 (men) 
and >0.8 (women) 
 Run-in adherence to study drug = 100% 
 Signed informed consent 
 Uncontrolled diabetes  
 Severe hypoglycemia in prior year 
 Coronary or cerebrovascular event in 
prior 2 months or plans to 
revascularize 
 eGFR <15 ml/min/1.73 m2 or on 
dialysis 
 Gastric bypass or emptying 
abnormality  
 Prior pancreatitis/concordant 
symptoms 
 Liver disease or ALT ≥3.0 X normal 
 Family history of/or C cell 
hyperplasia or medullary thyroid 
cancer or MEN 2A or 2B or 
calcitonin value ≥20 pg/mL 
 Unwilling to stop GLP1 RA or 
DPP4 inhibitor or weight loss drug 
 Cancer within prior 5 years  
 Pregnant or not using reliable birth 
control 
 Life expectancy < 1 year 
eGFR – estimated glomerular filtration rate; MEN – multiple endocrine neoplasia  
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Table 2: Secondary and Other Outcomes  
Secondary Outcomes Other Outcomes Safety Outcomes 
 Composite Microvascular 
Outcome: diabetic 
retinopathy needing laser, 
anti VEGF therapy, or 
vitrectomy; or clinical 
proteinuria; or a 30% decline 
in eGFR; or chronic renal 
replacement therapy 
 Unstable angina 
hospitalization 
 Heart failure hospitalization 
or urgent visit 
 Nonfatal MI 
 Nonfatal stroke 
 CV death 
 Death 
 HbA1c 
 Weight, and Waist/Hip 
Ratio 
 Expanded Composite CV 
Outcome: nonfatal MI, 
nonfatal stroke, unstable 
angina, hospitalization or 
cardiovascular death 
 Revascularization 
(coronary, carotid, or 
peripheral)  
 Any hospitalization  
 Any fracture 
 Cholelithiasis 
 Erectile dysfunction (men) 
 Cognitive decline 
 Acute pancreatitis 
 Serious GI events 
 Cancers: pancreatic, 
medullary thyroid, 
other thyroid, other 
(excluding non-
melanoma skin 
cancers) 
 Severe hypoglycemia 
 Immune reactions 
 Serious hepatic events 
 Serious renal events 
 Supraventricular 
arrhythmias and CV 
conduction disorders 
 Drug discontinuation 
The primary outcome for REWIND is the first occurrence of either a nonfatal myocardial infarction, 
nonfatal stroke, or cardiovascular death. VEGF - vascular endothelial growth factor; eGFR-estimated 
glomerular filtration rate; MI -Myocardial infarction; GI – gastrointestinal; CV - cardiovascular 
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Table 3: Baseline Clinical Characteristics of 9901 Randomized Participants 
Characteristic All Participants 
Age (years) – mean (SD) 66.2 (6.5) 
Females – N (%) 4589 (46.3) 
Geography  
  USA and Canada – N (%) 2071 (20.9) 
  Mexico and South America – N (%) 3021 (30.5) 
  Europe, Russia and South Africa – N (%) 4339 (43.8) 
  Asia: Taiwan and Korea – N (%) 148 (1.5) 
  Pacific: Australia and New Zealand – N (%) 322 (3.3) 
Prior cardiovascular disease (> 1 of the following 6) – N (%) 3111 (31.4) 
   Prior myocardial infarction – N (%) 1600 (16.2) 
   Prior ischemic stroke – N (%) 526 (5.3) 
   Prior unstable angina – N (%) 587 (5.9) 
   Prior revascularizationa  1787 (18.1) 
   Prior hospitalization for ischemia-related eventsb – N (%) 1193 (12.1) 
   Prior documented myocardial ischemia – N (%) 922 (9.3) 
Prior hypertension – N (%) 9223 (93.2) 
Prior heart failure – N (%) 852 (8.6) 
Prior diabetic retinopathy – N (%)  891 (9.0) 
Prior fracture – N (%) 1510 (15.3) 
Prior cholecystectomy – N (%) 1465 (14.8) 
Current tobacco use – N (%) 1407 (14.2) 
Diabetes duration (years) – mean (SD) 10.0 (7.2) 
Weight (kg) – mean (SD) 88.7 (18.5) 
Body Mass Index (kg/m2) – mean (SD) 32.3 (5.7) 
Blood pressure (mm Hg) – mean (SD) 137.2 (16.8)/78.5 (9.8) 
Pulse (beats/min) – mean (SD) 71.5 (10.9) 
Male Waist/Hip – mean (SD) 110.6 (13.1)/108.4 (11.2) 
Female Waist/Hip – mean (SD) 106.7 (13.1)/113.3 (13.7) 
HbA1c (%)– mean (SD)  7.3 (1.1) 
Cholesterol (mmol/L) – mean (SD) 4.52 (1.16) 
LDL cholesterol (mmol/L) – mean (SD) 2.56 (0.98) 
HDL cholesterol (mmol/L) – mean (SD) 1.18 (0.34) 
Triglycerides (mmol/L) – median (IQR) 1.60 (1.17, 2.22) 
eGFR (ml/min/1.73m2)c  – mean (SD) 77.6 (24.1) 
eGFR <60 – N (%)  2199 (22.2) 
Albumin/creatinine (mg/mmol) – median (IQR) 1.94  (0.75, 8.02) 
Macro or microalbuminuriad – N (%) 3491 (35.3) 
SD – standard deviation; IQR – interquartile range;  a coronary, carotid or peripheral; bunstable angina or 
myocardial ischemia on imaging, or need for percutaneous coronary intervention;  cestimated glomerular 
filtration rate; dalbumin/creatinine > 3.39 mg/mmol 
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 Table 4: Baseline Use of Drug Classes in 9901 Randomized Participants 
Diabetes Specific Drugs Classes Other Drug Classes 
None  600 (6.1) ACE-inhibitora 4909 (49.6) 
Only 1 oral agent 4926 (49.8) ARBb 3366 (34.0) 
Only 2 oral agents 3894 (39.3) ACE-inhibitor or ARB 8054 (81.4) 
Any insulin  2398 (24.2) Aldosteronec antagonist 464 (4.7) 
Metformin 8016 (81.0) All diuretic  4592 (46.4) 
Glibenclamide/glyburide  1271 (12.8) Thiazides  652 (6,6) 
Other sulfonylureas 4373 (44.2) Beta blocker 4502 (45.5) 
DPP4c inhibitors 88 (0.9) Ca Channel Blocker 3385 (34.2) 
SGLT2 inhibitors 12 (0.1) Acetylsalicylic Acid 5001 (50.5) 
Meglitinides 64 (0.7) Other Antiplatelet  820 (8.3) 
α glucosidase inhibitors 118 (1.2) Statin 6537 (66.0) 
Thiazolidinediones 168 (1.7) Fibrate 892 (9.0) 
Dopamine agonist 47 (0.5) Other lipid drug 112 (1.1) 
Other 84 (0.9) PPId 1673 (16.9) 
Values shown in the cells represent counts and percentage of all randomized;  aangiotensin converting 
enzyme; bangiotensin receptor blocker; cdipeptidyl peptidase 4;dproton pump inhibitor 
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Table 5: Key Characteristics of  Completed Trials and REWIND 
 ELIXA LEADER SUSTAIN 6 REWIND 
Drug tested Lisixenatide Liraglutide Semaglutide Dulaglutide 
Dose  20 ug/day 1.8 mg/day 0.5 or 1 mg/wk 1.5 mg/wk 
N 6068 9340 3297 9901 
Mean age (years) 
 
60 64 65 66 
Percent women 31 36 39 46 
Percent prior CVD 100 81 59 31 
Mean BMI (kg/m2) 30 33 31 32 
Mean HbA1c (%) 7.7 8.7 8.7 7.3 
Primary outcome MACE or 
unstable angina 
MACE MACE MACE 
MACE –Nonfatal myocardial infarction, nonfatal stroke or cardiovascular death; CVD – 
cardiovascular disease; BMI – body mass index 
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